Merck Eye Disease Drug Meets Main Goal in Trial

Merck's experimental eye disease drug has met its main goal in a mid-to late-stage trial. The company announced this on Thursday, September 24th. In the trial, adult patients with a specific type of retinal vessel disorder were tested.

The results showed that the Merck drug achieved the primary endpoint, though details about the trial's success rate and other specifics are not provided in the announcement. Reuters reported the news based on information from Christy Santhosh in Bengaluru, with editing by Sahal Muhammed.